CVS Health
CVS
$93.02
-0.67%
CVS Health is a diversified healthcare services company operating through retail pharmacy, pharmacy benefit management (PBM), and health insurance segments, serving millions of customers and members across the United States. As a market leader in integrated healthcare delivery, CVS combines its ~9,000 retail stores, Caremark PBM, and Aetna insurance to create a unique vertically integrated model. The current investor narrative centers on a potential turnaround, driven by a strong Q1 2026 earnings beat, improved medical cost ratios, and a favorable Medicare payment decision that added $13 billion in revenue visibility. The stock has rallied significantly over the past year, but recent volatility and a pullback from highs have sparked debate about whether the recovery is sustainable or if headwinds in the insurance segment persist.…
CVS
CVS Health
$93.02
Related headlines
CVS 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CVS Health's 12-month outlook, with a consensus price target around $116.08 and implied upside of +24.8% versus the current price.
Average Target
$116.08
0 analysts
Implied Upside
+24.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$103 - $148
Analyst target range
CVS has coverage from 25 analysts, with a consensus recommendation of 'Strong Buy' and a mean rating of 1.44 (where 1 is Strong Buy). The average target price is $116.08, implying an upside of 19.5% from the current price of $97.16. The target range is $103.00 to $148.00, with the low target still above the current price, indicating that even the most bearish analyst sees some upside. The high target of $148.00 assumes a successful turnaround with margin expansion and growth in the insurance segment, while the low target of $103.00 reflects concerns about competitive pressures and regulatory changes. Recent ratings from major firms like Wells Fargo, RBC, and Morgan Stanley are all positive (Overweight/Outperform), and there have been no downgrades in the past three months, suggesting strong conviction in the stock's recovery story.
Bulls vs Bears: CVS Investment Factors
CVS presents a compelling turnaround story with strong Q1 2026 earnings, a favorable Medicare decision, and a forward PE of 11.4x, which is a 48% discount to the industry. The bull case is supported by analyst consensus and improving margins, while the bear case centers on high debt, thin margins, and recent volatility. Currently, the bull evidence is stronger, given the earnings beat and regulatory tailwind, but the key tension is whether the earnings recovery is sustainable. If the insurance segment continues to improve and margins expand, the stock could re-rate higher; if not, the low forward PE may be justified by persistent risks.
Bullish
- Strong Q1 2026 earnings beat: Q1 2026 EPS of $2.31 significantly exceeded the prior year's $1.41, driven by a lower medical cost ratio and improved operational efficiency. This beat triggered a 24% rally and raised full-year guidance, signaling a potential sustainable turnaround.
- Favorable Medicare payment decision: A CMS decision added $13 billion in revenue visibility for 2027, boosting the insurance segment's outlook. This regulatory tailwind reduces uncertainty and supports the company's profit recovery narrative.
- Attractive forward valuation: With a forward PE of 11.4x versus the industry average of 22x, CVS trades at a 48% discount, implying the market is pricing in significant earnings growth. The PEG ratio of -0.92 further suggests undervaluation relative to expected earnings growth.
- Analyst consensus is Strong Buy: 25 analysts rate CVS a Strong Buy with a mean rating of 1.44, and the average target price of $116.08 implies 19.5% upside. No downgrades in the past three months indicate strong conviction in the recovery.
Bearish
- High debt burden: Debt-to-equity ratio stands at 1.24, and interest expense was $774 million in Q1 2026. This leverage increases financial risk, especially if interest rates remain elevated or cash flows weaken.
- Thin operating margin: Operating margin is only 4.7%, reflecting intense competition and regulatory pressures in the healthcare sector. This leaves little room for error and makes earnings vulnerable to cost overruns.
- Recent price volatility: The stock pulled back 8.3% in the past month and is down 12% from its July high of $110.60, indicating profit-taking and uncertainty about the sustainability of the rally. Beta of 0.596 suggests lower volatility, but the recent decline shows sensitivity to sentiment.
- Negative PEG ratio: The PEG ratio of -0.92 is negative due to expected earnings growth, but this also reflects the market's skepticism about the quality of that growth. If earnings fail to materialize, the stock could face de-rating.
CVS Technical Analysis
CVS is in a strong uptrend over the past year, with a 45.6% price increase, and the current price of $97.16 sits at 87.8% of its 52-week range (low $67.42, high $110.68). This positioning near the upper end of the range suggests robust momentum, but the stock is off its July high of $110.60, indicating some profit-taking after a sharp run. The 6-month change of +23.8% and YTD change of +21.3% confirm a sustained bullish trend, though the stock is currently below its recent peak, suggesting a potential consolidation phase.
Beta
0.60
0.60x market volatility
Max Drawdown
-16.4%
Largest decline past year
52-Week Range
$70-$111
Price range past year
Annual Return
+30.2%
Cumulative gain past year
| Period | CVS Return | S&P 500 |
|---|---|---|
| 1m | -13.9% | +2.5% |
| 3m | -0.3% | +2.7% |
| 6m | +21.3% | +11.1% |
| 1y | +30.2% | +20.5% |
| ytd | +16.1% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CVS Fundamental Analysis
CVS's revenue trajectory is solid, with Q1 2026 revenue of $100.4 billion, up 6.2% year-over-year, and a sequential increase from Q4 2025's $105.7 billion. The company's diverse revenue streams, including pharmacy revenue of $56.9 billion and premiums of $33.8 billion, provide stability, but growth is moderate. Net income in Q1 2026 was $2.94 billion, a significant improvement from the loss in Q3 2025, and the net margin of 2.9% shows recovery. Gross margin improved to 15.6% in Q1 2026, up from 12.8% in Q4 2025, indicating better cost management. However, operating margin remains thin at 4.7%, reflecting the competitive and regulatory pressures in the healthcare sector.
Quarterly Revenue
$100.4B
2026-03
Revenue YoY Growth
+6.2%
YoY Comparison
Gross Margin
15.6%
Latest Quarter
Free Cash Flow
$7.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CVS Overvalued?
Given that CVS is profitable, the PE ratio is the primary valuation metric. The trailing PE is 56.7x, while the forward PE is 11.4x, a massive gap that implies the market expects a significant earnings recovery. This is supported by the PEG ratio of -0.92, which is negative due to expected earnings growth, but the forward PE suggests the stock is undervalued relative to its near-term earnings power. Compared to the industry average PE of 22x, CVS's forward PE of 11.4x represents a 48% discount, which may be justified by its lower margins and high debt levels. Historically, CVS's PE has ranged from 7.8x to 227x over the past year, and the current forward PE is near the lower end, indicating potential value if the company can sustain its earnings recovery.
PE
56.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 8x~26x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
18.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant. CVS carries a high debt-to-equity ratio of 1.24, with interest expense of $774 million in Q1 2026, which could strain cash flows if rates rise. The operating margin is thin at 4.7%, leaving limited buffer against cost inflation or revenue shortfalls. Revenue growth is moderate at 6.2% YoY, and the company's reliance on the insurance segment for profit recovery adds concentration risk. Additionally, the payout ratio of 192% indicates the dividend is not fully covered by earnings, posing a risk of future cuts.